MATERIAL SAFETY DATA SHEET

Product Name: Propofol Injectable Emulsion 1%

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

Manufacturer Name: Hospira, Inc.
And Address: 275 North Field Drive
Lake Forest, Illinois 60045
USA

Note: Hospira, formerly the Hospital Products Division of Abbott Laboratories, was created as an independent company in May 2004.

Emergency Telephone: CHEMTREC: 800 424-9300
Hospira, Inc.: 224 212-2055

Product Name: Propofol Injectable Emulsion 1%
Synonyms: 2,6 – Diisopropylphenol, 2-6-DIP

2. COMPOSITION/INFORMATION ON INGREDIENTS

Ingredient Name: 2,6 - Diisopropylphenol
Chemical Formula: C₁₂H₁₈O

<table>
<thead>
<tr>
<th>Component</th>
<th>Approximate Percent by Weight</th>
<th>CAS Number</th>
<th>RTECS Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>2,6 - Diisopropylphenol</td>
<td>1.0</td>
<td>2078-54-8</td>
<td>SL08100000</td>
</tr>
<tr>
<td>Benzyl Alcohol</td>
<td>0.2</td>
<td>100-51-6</td>
<td>DN3150000</td>
</tr>
<tr>
<td>Non-hazardous ingredients*</td>
<td>14</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Water</td>
<td>85</td>
<td>7732-18-5</td>
<td>ZC0110000</td>
</tr>
</tbody>
</table>

Non-hazardous ingredients include Egg Lecithin, Soybean Oil, and Glycerin.

3. HAZARD INFORMATION

Emergency Overview: Propofol Injectable Emulsion is a phenolic compound used to induce and maintain anesthesia and sedation. It is administered intravenously. Target organs include the central nervous system.

Occupational Exposure Potential: Information on the absorption of this compound via ingestion and inhalation is not available.

Signs and Symptoms: No signs or symptoms from occupational exposure are known. Clinical data suggest adverse effects include slowed heart rate, decreased blood pressure, transient apnea, rash and cough. Reported to cause eye and skin irritation.

Medical Conditions Aggravated by Exposure: None Known.
### 4. FIRST AID MEASURES

**Eye Contact:** Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Skin Contact:** Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Inhalation:** Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Ingestion:** Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

### 5. FIRE FIGHTING MEASURES

<table>
<thead>
<tr>
<th>Property</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Flammability:</strong></td>
<td>Flash Point 234°F</td>
</tr>
<tr>
<td><strong>Fire &amp; Explosion Hazard:</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Extinguishing Media:</strong></td>
<td>Use extinguishing media appropriate for primary cause of fire.</td>
</tr>
<tr>
<td><strong>Special Fire Fighting Procedures:</strong></td>
<td>No special provisions required beyond normal fire fighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.</td>
</tr>
</tbody>
</table>

### 6. ACCIDENTAL RELEASE MEASURES

**Spill Cleanup and Disposal** Absorb with suitable material and clean affected area with soap and water. Dispose of materials according to the applicable federal, state, or local regulations.

### 7. HANDLING AND STORAGE

**Handling** No special handling required.

**Storage** No special storage required for hazard control. For product protection, store at temperatures of 4 - 22°C (40 - 72°F). Do not freeze.

**Special Precautions** None
Product Name: Propofol Injectable Emulsion 1%

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

<table>
<thead>
<tr>
<th>Component</th>
<th>OSHA-PEL</th>
<th>ACGIH-TLV</th>
<th>Hospira EEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>2,6 - Diisopropylphenol</td>
<td>8 hr TWA: Not Established</td>
<td>8 hr TWA: Not Established</td>
<td>8 hr TWA: 2.0 mg/m³ STEL: 10.0 mg/m³</td>
</tr>
</tbody>
</table>

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit
ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.
EEL: Employee Exposure Limit.
TWA: 8 hour Time Weighted Average.
STEL: 15-minute Short Term Exposure Limit.

Respiratory Protection
Respiratory protection is not needed during normal product use.

Skin Protection
If solution contact with unprotected skin is likely, impervious gloves are a prudent practice.

Eye Protection
Eye protection is not required during typical product use conditions but may be warranted should a splash potential exist.

Engineering Controls
Engineering controls are not needed during normal product use conditions.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State
White, oil-in-water emulsion.

Odor
Slight phenolic odor

Boiling Point
242° C (468° F)

Freezing Point
Approximately that of water.

Vapor Pressure
0.142 mm Hg @ 20° C

Vapor Density (Air=1)
Not Determined

Evaporation Rate
Approximately that of water.

Bulk Density
Not Determined

Specific Gravity
0.955

Solubility
Soluble in water

pH
7.0 – 8.5

10. STABILITY AND REACTIVITY

Chemical Stability
Stable

Incompatibilities
None known.

Hazardous Decomposition Products
Carbon monoxide, carbon dioxide.

Hazardous Polymerization
Not expected.
11. TOXICOLOGICAL INFORMATION:

<table>
<thead>
<tr>
<th>Ingredient(s)</th>
<th>Percent</th>
<th>Test Type</th>
<th>Value</th>
<th>Units</th>
<th>Species</th>
</tr>
</thead>
<tbody>
<tr>
<td>2,6 - Diisopropylphenol</td>
<td>100</td>
<td>LD50</td>
<td>518-1230</td>
<td>mg/kg</td>
<td>Rats, Mice</td>
</tr>
<tr>
<td>2,6 - Diisopropylphenol</td>
<td>100</td>
<td>LD50</td>
<td>&gt; 2000</td>
<td>Mg/kg</td>
<td>Rabbits</td>
</tr>
</tbody>
</table>

*LD50 is the dosage producing 50% mortality.*

*Product contains approximately 1% 2, 6-Diisopropylphenol.*

- **Mutagenicity**: Not Known
- **Dermal Irritation**: Reported to have the potential to produce slight skin irritation.
- **Ocular Irritation**: Reported to have the potential to produce slight eye irritation.
- **Target Organ Effects**: In clinical use target organ effects include the central nervous system.
- **Carcinogenicity**: Not Known

12. ECOLOGICAL INFORMATION:

- **Aquatic Toxicity**: Not Available

13. DISPOSAL CONSIDERATIONS:

- **Waste Disposal**: Disposal should be performed in accordance with the federal, state or local regulatory requirements.
- **Container Handling and Disposal**: Dispose of container and unused contents in accordance with federal, state, and local regulations.

14. TRANSPORTATION INFORMATION

- **DOT Status**: Not Regulated
  
- **Notes**: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

- **TSCA Status**: Not Regulated
- **CERCLA Status**: Not Regulated
- **SARA Status**: Not Regulated
- **RCRA Status**: Not Regulated
- **PROP 65 (Calif.)**: Not Regulated

*Notes:* TSCA, Toxic Substance Control Act
CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
SARA, Superfund Amendments and Reauthorization Act
RCRA, US EPA, Resource Conservation and Recovery Act
Prop 65, California Proposition 65

16. OTHER INFORMATION:

- **MSDS Coordinator**: T. Straits MPH, CIH
- **Date Prepared**: March 17, 2006

**Disclaimer:**

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.